A registered randomized controlled trial (NCT07294950) from Mount Sinai Hospital, Toronto, will compare gradual 16-week semaglutide dose tapering against abrupt discontinuation in adults with obesity who achieved ≥10% weight loss. Primary endpoint is percentage body weight change between arms; secondary endpoints include 24-hour ambulatory blood pressure and fasting ghrelin — a hunger-signaling hormone that rebounds sharply when GLP-1 receptor agonists are withdrawn.
The clinical urgency here is real. Post-discontinuation weight regain with semaglutide averages roughly two-thirds of lost weight within one year, as shown in the STEP 1 extension trial — an outcome that undermines the cardiovascular and metabolic gains patients worked to achieve. The REST trial's hypothesis that tapering may blunt this rebound is physiologically plausible: gradual dose reduction could allow endogenous appetite-regulating circuits, particularly ghrelin and hypothalamic GLP-1 sensitivity, to recalibrate rather than snap back abruptly. Measuring ghrelin is a smart mechanistic choice that distinguishes this protocol from simpler weight-tracking designs.
However, what's being analyzed here is a study protocol — not results. No efficacy data exist yet, and the intervention window (16 weeks of tapering) may be insufficient to reset the long-term adipostat. The finding that most people need to remain on these medications indefinitely for sustained benefit remains the dominant clinical reality. This trial is timely and methodologically sound, but its practical impact depends entirely on outcomes yet to be collected.